| Literature DB >> 12500288 |
Abstract
Various integrin antagonist candidates including antibodies, cyclic peptides, peptidomimetics, and non-peptides have been clinically evaluated and shown to successfully modulate certain disease processes. This review will focus on the key role of the alphav integrin (alphavbeta3 and alphavbeta5) in vascular disorders such as restenosis and angiogenesis-mediated disorders. Copyright 2002 Wiley Periodicals, Inc.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12500288 DOI： 10.1002/med.10031
Source DB: PubMed Journal: Med Res Rev ISSN： 0198-6325 Impact factor: 12.944